Abiomed (ABMD) Impella Approved for Reimbursement in the Netherlands
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Down)Join SI Premium – FREE
Abiomed, Inc. (Nasdaq: ABMD) announced that the Netherlands has approved new reimbursement coding and payment for the Impella product. The new coding allows for hospitals to receive funding for the use of the Impella technology in a broad set of clinical indications of heart disease through the process known as Diagnosis Treatment Combinations (Diagnose Behandeling Combinaties; DBCs), similar to the Medicare Diagnosis-Related Group (DRG) system in the United States.
New reimbursement is a significant milestone for the recognition of Impella as a required therapy for treatment of heart disease in the European hospital setting. The Netherlands has also been a leader in early clinical and cost effectiveness research of the Impella technology under the leadership of Dr. Jose Henriques at the Amsterdam Medical Center.
New reimbursement is a significant milestone for the recognition of Impella as a required therapy for treatment of heart disease in the European hospital setting. The Netherlands has also been a leader in early clinical and cost effectiveness research of the Impella technology under the leadership of Dr. Jose Henriques at the Amsterdam Medical Center.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Connect Biopharma (CNTB) Reports Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial
- AppLovin (APP) Files Mixed Shelf
- Chemours (CC) to Sell Glycolic Acid Business to Iron Path Capital-backed PureTech Scientific for $137M
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
